|Mr. Raj Kannan||CEO, Principal Financial Officer & Director||753.49k||N/A||1964|
|Dr. Casey C. Kopczynski Ph.D.||Co-Founder, Chief Innovation Officer & Head of Research and External Innovation||685.06k||983.39k||1961|
|Mr. John W. LaRocca Esq.||Gen. Counsel & Sec.||676.62k||N/A||1965|
|Mr. Peter F. Lang||Chief Financial Officer||N/A||N/A||1972|
|Dr. Michelle Senchyna Ph.D.||Head of Clinical Devel. & Operations||N/A||N/A||N/A|
|Mr. Jeffrey M. Calabrese CPA||VP of Fin. & Principal Accounting Officer||N/A||N/A||1967|
|Ms. Carolyn McAuliffe||Sr. Director of Communications||N/A||N/A||N/A|
|Ms. Wanda Francies||Head of HR||N/A||N/A||N/A|
|Mr. Marvin J. Garrett||Head of Regulatory Affairs & Quality Assurance||N/A||N/A||1951|
|Mr. Craig R. Skenes||Head of Bus. Devel.||N/A||N/A||N/A|
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
Aerie Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 July 2022 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder rights: 8; Compensation: 7.